Forte Biosciences, Inc. Common Stock (FBRX) stock analysis and AI prediction
The company facts of Forte Biosciences, Inc. Common Stock, with its price and AI prediction for the next 10 market days in SharePreds.
Keep looking in SharePreds
You have looked at today's stocks on this website. SharePreds shows every stock's likelihood of rising, its chart and how its earlier predictions ended, with alerts on the ones you follow.
See all five apps
About Forte Biosciences, Inc. Common Stock
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
- Sector
- Healthcare
- Exchange
- NASDAQ
- Market value
- $1.6 billion
- Size
- Small cap
- Employees
- 23
- Headquarters
- DALLAS, TX
- Listed since
- June 16, 2020
- Website
- fortebiorx.com
More Healthcare stocks
Other small cap stocks
Keep going
FBRX questions
What is the AI prediction for FBRX stock?
Each market day our model rates Forte Biosciences, Inc. Common Stock (FBRX) Bullish, Neutral or Bearish for the next 10 market days. Predictions are indicative: they rest on price and volume data, and they can be wrong.
How often is the FBRX prediction updated?
Each market day, Monday to Friday, except market holidays. The date of the prediction is shown beside it.
What do Bullish, Neutral and Bearish mean?
Bullish means the model sees a rise as likely over the next 10 market days, Bearish a fall, and Neutral no clear direction.
Where can I see the exact likelihood for FBRX?
In the SharePreds app for iPhone and Android, with the stock's chart, alerts on it and how its earlier predictions ended.
Where can I see FBRX options?
The FBRX options page opens its calls and puts, with price, volume, implied volatility and the Greeks.